{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:08:48Z","timestamp":1786118928814,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1097\/shk.0b013e318181a6e4","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T03:27:12Z","timestamp":1221017232000},"page":"67-69","source":"Crossref","is-referenced-by-count":1,"title":["TREATMENT OF SEVERE INFECTIONS CAUSED BY STAPHYLOCOCCUS AUREUS"],"prefix":"10.1097","volume":"30","author":[{"given":"Luis Fernando","family":"Aranha Camargo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"6","key":"R1-13-20210213","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3201\/eid1106.040831","article-title":"Methicillin-resistant-Staphylococcus aureus hospitalizations, United States.","volume":"11","author":"Kuehnert","year":"2005","journal-title":"Emerg Infect Dis"},{"issue":"8","key":"R2-13-20210213","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1086\/501795","article-title":"Nosocomial infections in combined medical-surgical intensive care units in the United States.","volume":"21","author":"Richards","year":"2000","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"3","key":"R3-13-20210213","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.","volume":"39","author":"Wisplighoff","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"8","key":"R4-13-20210213","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1001\/jama.1995.03530080055041","article-title":"The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee.","volume":"274","author":"Vincent","year":"1995","journal-title":"JAMA"},{"key":"R5-13-20210213","doi-asserted-by":"crossref","first-page":"582","DOI":"10.7326\/0003-4819-145-8-200610170-00007","article-title":"Device-associated nosocomial infections in 55 intensive care units of 8 developing countries.","volume":"145","author":"Rosenthal","year":"2006","journal-title":"Ann Intern Med"},{"issue":"6","key":"R6-13-20210213","doi-asserted-by":"crossref","first-page":"R422","DOI":"10.1186\/cc2965","article-title":"Ventilator associated pneumonia: comparison between quantitative and qualitative cultures of tracheal aspirates.","volume":"8","author":"Camargo","year":"2004","journal-title":"Crit Care"},{"issue":"12","key":"R8-13-20210213","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1469-0691.2003.00698.x","article-title":"Epidemiology of methicillin-resistant staphylococci in Europe.","volume":"9","author":"Stefani","year":"2003","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"R9-13-20210213","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijantimicag.2003.12.019","article-title":"Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001.","volume":"24","author":"Streit","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"R10-13-20210213","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1017\/S0950268800030478","article-title":"High-level vancomycin-resistant enterococci causing hospital infections.","volume":"103","author":"Uttley","year":"1989","journal-title":"Epidemiol Infect"},{"issue":"7","key":"R11-13-20210213","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJM199902183400701","article-title":"Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.","volume":"340","author":"Mith","year":"1999","journal-title":"N Engl J Med"},{"issue":"14","key":"R12-13-20210213","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJMoa025025","article-title":"Vancomycin-Resistant Staphylococcus aureus Investigative Team. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene.","volume":"348","author":"Chang","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"R13-13-20210213","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/jac\/37.2.209","article-title":"The comparative efficacy and safety of teicoplanin and vancomycin.","volume":"37","author":"Woods","year":"1993","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"R14-13-20210213","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2307\/30141354","article-title":"Risk factors for mortality in Staphylococcus aureus bacteremia.","volume":"19","author":"Conterno","year":"1998","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"1","key":"R15-13-20210213","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1086\/345476","article-title":"Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis.","volume":"36","author":"Cosgrove","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"4","key":"R16-13-20210213","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1086\/346207","article-title":"Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001.","volume":"36","author":"Fridkin","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"9","key":"R17-13-20210213","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1086\/513203","article-title":"The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus.","volume":"44","author":"Tenover","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"6","key":"R18-13-20210213","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1128\/JCM.42.6.2398-2402.2004","article-title":"Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.","volume":"42","author":"Sakoulas","year":"2004","journal-title":"J Clin Microbiol"},{"issue":"2","key":"R19-13-20210213","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1128\/AAC.37.2.281","article-title":"Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients.","volume":"37","author":"Lamer","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"R20-13-20210213","first-page":"1632","article-title":"Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.","volume":"124","author":"Wunderink","year":"2003","journal-title":"Chest"},{"key":"R21-13-20210213","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s00134-003-2088-1","article-title":"Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin.","volume":"30","author":"Kollef","year":"2004","journal-title":"Intensive Care Med"},{"issue":"7","key":"R22-13-20210213","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"R23-13-20210213","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1086\/427283","article-title":"Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens.","volume":"40","author":"Raad","year":"2005","journal-title":"Clin Infect Dis"}],"container-title":["Shock"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/SHK.0b013e318181a6e4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:08:17Z","timestamp":1786036097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00024382-200810001-00013"}},"subtitle":["A CHANGE IN THE VANCOMYCIN PARADIGM?"],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/shk.0b013e318181a6e4","relation":{},"ISSN":["1073-2322"],"issn-type":[{"value":"1073-2322","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}